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Serum rheumatoid factor (RF) is important in the diagnosis
and prognosis of rheumatoid arthritis (RA). The purpose of this
study is to compare the clinical characteristics and treatment
patterns of RA according to the presence of RF in Korean
patients. A retrospective analysis was performed on the
records of 109 patients who were followed for at least 2 years,
among 230 RA patients who visited at the rheumatology clinic
in Ajou University Hospital and who fulfilled the 1987 revised
American College of Rheumatology criteria for RA. Sixty-four
patients were RF positive (58.7%) and 91 patients were female
(83.5%). There was no significant difference in demographic
characteristics, joint involvements, or percentage of morning
stiffness between seropositive and seronegative groups. Anti-
nuclear antibody was detected more frequently in the sero-
positive group (p<0.05). At initial diagnosis, the seropositive
group had higher white blood cell and platelet counts than the
seronegative group (p<0.01). However, the difference was
disappeared at the last follow-up. Inflammatory markers such
as ESR and CRP were also higher at diagnosis in the sero-
positive group (p<0.01). These inflammatory markers were
still greater than the seronegative group at the last follow-up
(p<0.01). There was no significant difference in the use of
disease modifying antirheumatic drug (DMARD) and steroid
dosage between groups. However, DMARD combination
therapy was more commonly used in the seropositive group
(p<0.05), especially triple DMARD combination. These
results suggest that disease activity is more severe in the
seropositive than the seronegative group, and more aggressive
treatments are needed in the seropositive group.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflam-
matory disease that predominantly manifests as
persistent synovial inflammation of peripheral
joints. Severity and prognosis of RA are influ-
enced by a variety of demographic factors, such
as race, gender, age, profession, and educational
level. Clinical factors, such as symptom duration,
number of involved joints, rheumatoid nodule,
systemic manifestations, and radiologic changes at
initial diagnosis are important prognostic fac-
tors.
1,2 Also, erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), and rheumatoid factor
(RF) are useful laboratory findings affecting the
prognosis of RA.
2,3
RF is an antibody against the Fc portion of im-
munoglobulin G. RF was first described by
Waaler and Rose in 1940,
4 and Pike stated in 1949
that RF could be utilized as a diagnostic criteria
in RA.
5 RF is observed not only in RA, but also
in other rheumatic diseases like Sjogren's syn-
drome, systemic lupus erythematosus, polymyo-
sitis and dermatomyositis, and in inflammatory
diseases such as chronic hepatitis. Even in healthy
people, RF levels increase with age, and positive
reactions can be seen in 5% of young people and
up to 25% of the elderly. RF is an important
laboratory parameter because RF positive RA
patients have more frequent joint deformity and
extra-articular manifestation than RF negative
patients. Also, the possibility of developing RA is
high in healthy people with RF.
6,7
In this study, we tried to make a retrospective
comparison of clinical and laboratory charac-
teristics and treatment patterns according to RF
status at diagnosis.
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MATERIALS AND METHODS
The clinical characteristics of 109 RA patients
whose follow-up period was more than two years
were studied retrospectively from a total of 230
patients with RA who were cared for at the
rheumatology clinic in Ajou University Hospital
from June 1995 to March 2002. At the time of
diagnosis, the patients satisfied the 1987 revised
American College of Rheumatology criteria for
classification of RA. Patients diagnosed before 16
years of age were excluded. Patients with arthritis
due to other disease, such as gout, ankylosing
spondylitis, Reiter's syndrome, psoriasis, inflam-
matory bowel disease, systemic lupus erythema-
tosus, Behçet's disease, and adult onset Still's
disease were also excluded.
Patient records were reviewed and a standard
form was used for all relevant clinical information
on demographic, clinical, laboratory, and thera-
peutic characteristics from the time of diagnosis
until the end of the study period. All clinical in-
formation was entered into a computer database.
The patients were divided into seropositive and
seronegative groups. A patient was considered
seropositive if the IgM RF test result was higher
than 40IU/ml and seronegative if IgM RF was less
than that.
The following parameters were recorded for
each patient at the time of diagnosis: age, gender,
duration of symptoms before diagnosis, length of
follow-up, family history of RA, morning stiffness,
and distribution of involved joints. The following
extraarticular manifestations during the disease
period were also noted: rheumatoid nodule, vas-
culitis, serositis, episcleritis, and sicca symptoms.
We documented ESR, CRP, hematocrit, white
blood cell (WBC) count, and platelet count at the
initial diagnosis and at the last follow-up. Also,
ANA result was verified. The patients had X-rays
of their hands and feet taken at their first visit,
and some patients had follow-up X-rays. These
were reviewed using the Steinbrocker grading
system (grades I-IV) by one radiologist.
With regard to the treatment, we recorded the
use of NSAID, the use of each disease modifying
anti-rheumatic drug (DMARD), and the incidence
of DMARD combination treatment. We used
DMARD combination therapy in double and tri-
ple DMARD combinations according to the dis-
ease severity assessed by the patients symptoms
(morning stiffness and visual analogue pain scale),
physical findings (tender joint count and swollen
joint count), and inflammation markers (ESR and
CRP). Finally, steroid usage was measured in two
ways; mean steroid dose, which was calculated by
dividing the total amount of steroid (mg of pre-
dnisone equivalent) used during the study period
by the days of disease duration, and maximum
steroid dose, which was the highest daily steroid
dose used during the study period.
For statistical analysis of clinical and laboratory
data derived from the patient groups, SPSS ver-
sion 10.0 (Statistical Package for the Social Sci-
ences, Chicago, IL) was utilized for descriptive
statistical analysis, χ
2-test, and independent t-test.
Results were specified as means with standard
deviation. A p-value of 0.05 or below was re-
garded as significant.
RESULTS
Clinical features
Among the 109 patients, 64 (58.7%) were sero-
positive and 45 (41.3%) were seronegative (Table
1). In the seropositive group, the male-female ratio
was 1:4.3, with 12 men and 52 women. The male-
female ratio was 1:6.5 in the seronegative group,
with 6 men and 39 women. The mean age at diag-
nosis of RA was 46.2 ± 14.5 years (range: 16-75
years) for the seropositive group and 43.6 ± 13.8
years (range: 20-75 years) for the seronegative
group (Fig. 1). Regarding symptom duration
before diagnosis, the seropositive group reported
30.9 ± 26.8 months, while the seronegative group
reported 21.5 ± 21.1 months. This long symptom
duration is probably related to the fact that our
clinic is a tertiary referral hospital. Total follow-up
period was 36.6 ± 16.8 and 35.5 ± 17 months,
respectively. Regarding morning stiffness, there
was no statistically significant difference between
groups, as it was present in 85% and 93% of
patients, respectively. There was no difference in
the total number of involved joints and both
groups showed nearly identical frequency of joint
involvement in the following order; finger jointsYoo-Seob Shin, et al.
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[metacarpophalangeal (MCP) joints and proximal
interphalangeal (PIP) joints], knee joints, elbow
joints and shoulder joints, wrist joints, ankle
joints, and toe joints (Fig. 2). Only ankle joints
were more frequently involved in the seropositive
group (p<0.05). Fourteen seropositive and 5 sero-
negative patients had family history of RA. The
number of patients with sicca syndrome was 8 of
64 in the seropositive group and 8 of 45 in the
seronegative group. Regarding cases of rheuma-
toid nodule, there were only 3 and 2 respectively
from each group, which was statistically insig-
nificant. The incidence of extraarticular manifes-
tation may be lower because of the retrospective
nature of this study.
Laboratory features
There was significant difference in ANA posi-
tive results according to RF status (Table 1).
Fig. 1. Age distribution of rheumatoid factor positive and
negative rheumatoid arthritis patients.
Fig. 2. Involved joints according to rheumatoid factor
status.
Table 1. Demographic Characteristics of the Study Subjects
Seropositive
(N=64)
Seronegative
(N=45)
p-value
Male 12 6 NS
Female 52 39 NS
M:F ratio 1:4.3 1:6.5 NS
Age at diagnosis (yrs)
Mean 46.2 ± 14.5 43.6 ± 13.8 NS
Range 16 - 75 20 - 75
Disease duration before dianosis (months) 30.9 ± 59.5 21.5 ± 44.9 NS
Follow-up (months) 36.6 ± 16.8 35.5 ± 17.0 NS
Morning stiffness 85% 93% NS
ANA (% positive) 31% 13% <0.05
Radiographic score (%)
Steinbrocker I+II 84.1% 89.7% NS
Steibrocker III+IV 15.9% 10.3% NS
ANA, antinuclear antibody; NS, not significant.Rheumatoid Factor in Rheumatoid Arthritis
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Thirty-one percent of the seropositive group were
positive for ANA, but only 13% in the RF negative
group (p<0.05). Hematocrit level at initial diag-
nosis and last follow-up was not different
between seropositive and seronegative groups
(Fig. 3). In each group, WBC counts were 8045 ±
2543/ L and 6836 μ ± 1957/ L respectively ( μ p <
0.01) at diagnosis, and 7154 ± 2397/ L and 6436 μ ±
1908/ L, respectively ( μ p=0.09) at the final fol-
low-up. Also, platelet counts showed 305 ± 81.7 ×
10
3/ L and 264.4 μ ± 83.2 × 10
3/ L, respectively ( μ p
<0.01) at diagnosis, and 275.9 ± 80.5×10
3/ L and μ
257.9 ± 72.3×10
3/ L, respectively ( μ p=0.23) at the
final follow-up. At the beginning of RA, seroposi-
tive patients showed higher WBC counts and
platelet counts as a marker of acute inflam-
mation, but the difference gradually disappeared
with treatment. During the entire follow-up pe-
riod, cumulative inflammation was higher in the
seropositive than the seronegative group.
The ESR at diagnosis was 49.1± 36.8 mm/hr and
26.6 ± 24.3 mm/hr (p<0.01) in seropositive and
seronegative groups, respectively (Fig. 4). Fol-
lowing treatment, ESR levels gradually decreased
Fig. 3. Hematologic cell counts according to rheumatoid
factor status. (A) Hematocrit levels were not different
between seropositive and seronegative groups; (B) white
blood cell (WBC) counts were higher in the seropositive
group at diagnosis, but differences between groups dis-
appeared at the final follow-up; (C) platelet counts mim-
icked the WBC trend. *p<0.05, **p<0.01, NS: not signifi-
cant.
Fig. 4. Inflammatory markers according to rheumatoid
factor status. (A) erythrocyte sedimentation rate (ESR)
was higher in the seropositive group at diagnosis and
throughout the follow-up; (B) C-reactive protein (CRP)
followed the ESR trend. **p<0.01.
A
B
C
A
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to 26.1±20.8mm/hr and 16±9.4mm/hr, respecti-
vely (p<0.01) at the final follow-up. The same
trend was noted in CRP levels; 2.9 ± 4.1 mg/dL
and 0.8 ± 1.2 mg/dL (p<0.01) was observed at
diagnosis, while 0.6 ± 1.1 mg/dL and 0.2 ± 0.4
mg/dL (p<0.01) was observed at the final follow-
up in seropositive and seronegative groups,
respectively. These results revealed that the
seropositive group had more inflammation than
the seronegative at diagnosis and throughout the
follow-up period. The treatment of RA could
decrease but not eliminate the inflammation, as
the seropositive group had more inflammation
than the seronegative at the last follow-up.
Radiologically, there were no statistically signi-
ficant differences between groups (Table 1). How-
ever, in the seropositive group, seven patients
showed progression on their follow-up X-rays. In
the seronegative group, two patients showed pro-
gression and one patient showed improvement.
Treatment according to RF status
As DMARD, hydroxychloroquine, sulfasalazine,
methotrexate, and bucillamine were used during
the study period. Hydroxychloroquine was most
commonly prescribed in both groups; 58 patients
(90.6%) of the seropositive and 36 patients (80%)
of the seronegative group (Table 2). Sulfasalazine
and methotrexate were also frequently used; in
the seropositive group, 54 patients (84.4%) and 47
patients (73.4%), respectively, and in the seronega-
tive group, 37 patients (82.2%) and 27 patients
(60%), respectively. There was no difference in the
use of DMARD between groups. However, more
patients were prescribed a combination of
DMARD in the seropositive than the seronegative
group; 59 patients (92.2%) vs. 32 patients (71.1%),
respectively (p<0.003). Triple DMARD combina-
tion therapy was also more commonly used in the
seropositive group (30 patients, 46.9%) vs. the
seronegative group (13 patients, 28.9%) (p < 0.05).
There was no difference in the mean steroid dose
between the seropositive and seronegative groups
(Fig. 5): 4.07 ± 2.98 mg/day and 3.27 ± 3.01 mg/
day, respectively (p=0.16). Also, the maximum
steroid dose of each group was not different: 8.49
Table 2. DMARD Usage According to Rheumatoid Factor Result
Seropositive (N=64) Seronegative (N=45)
p-value
n % n %
Hydroxychloroquine 58 90.6 36 80 NS
Sulfasalazine 54 84.4 37 82.2 NS
Methotrexate 47 73.4 27 60 NS
Bucillamine 1 1.6 2 4.4 NS
Combination 59 92.2 32 71.1 <0.01
Double combination 29 45.3 19 42.2 NS
Triple combination 30 46.9 13 28.9 <0.05
NS, not significant; DMARD, disease modifying antirheumatic drug.
Fig. 5. Comparison of corticosteroid dose according to
rheumatoid factor status. Steroid-max: the highest daily
steroid dose (mg of prednisone equivalent) used during
study period; Steroid-mean: total amount of steroid used
during study period divided by the days of disease
duration; NS, not significant.Rheumatoid Factor in Rheumatoid Arthritis
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± 4.12 mg/day and 7.5 ± 4.46 mg/day, respec-
tively (p=0.26). These results showed that the sero-
positive group was treated with more aggressive
treatment such as DMARD combinations, pro-
bably due to presenting with more severe clinical
disease activity.
DISCUSSION
RA is a chronic inflammatory disease that has
various clinical courses. Prognosis is influenced
by demographic factors, clinical factors, and
radiologic changes at initial diagnosis. Also, ESR,
CRP, and RF at diagnosis are laboratory factors
that affect the prognosis of RA.
1-3 We planned to
evaluate the clinical characteristics and treatment
strategy according to RF status in Korean RA
patients, because the clinical manifestations and
prognosis of RA could be different upon race.
8
Moreover, there had been no such study in Korea
to date. In this study, there was no difference in
clinical characteristics such as gender, age at
diagnosis, symptom duration before diagnosis,
follow-up period, and presence of morning stif-
fness according to RF status. Joint involvement
was not different, except that the ankle joint was
more frequently affected in the seropositive
group. From a study by Papadopoulos et al. in
Greece, male-female ratio, age at diagnosis, dis-
ease duration, and morning stiffness were not
significantly different between seropositive and
seronegative groups. However, seropositive
patients had a longer follow-up period, more fre-
quent involvement of hand joint, and higher in-
volved joint counts than the seronegative group.
9
Furthermore, a report indicated that rheumatoid
nodule was highly reported in seropositive
patients.
10 When Van de Heijde et al. checked the
factors related to poor prognosis in RA, they
found that woman, RF positive status, high ESR
and CRP, anemia, and rheumatoid nodule were
associated with poor outcomes.
3
We noticed more severe inflammation in the
seropositive group as well as increased ESR and
CRP levels at diagnosis and continuously during
follow-up. Also, WBC and platelet counts were
higher in seropositive patients at diagnosis,
however they were not at last follow-up. It could
be because the inflammation decreased due to
DMARD treatment and cell counts were less
sensitive to inflammatory markers such as ESR
and CRP. Amos et al. reported that RA patients
with high ESR and CRP have serious radiological
changes including bony erosion, regardless of RF
status.
11 It was revealed in a further study that the
seropositive group shows a higher inflammation
degree, lower hemoglobin level, and increased
WBC and platelet levels than the seronegative
group.
12,13 Regarding limitations of this retrospec-
tive study, we couldn't measure the radiologic
changes of all study patients. However, there were
no statistically significant differences between
groups except that all RF positive patients showed
progression on follow-up X-rays.
In our Korean RA patients, 31% of seropositive
patients showed positive ANA results, while only
13% of the seronegative group did. Though only
a few studies regarding the appearance of ANA
in RA have been made so far, a Japanese report
showed that 35% of RA patients were ANA
positive in a speckled or homogeneous pattern.
14
Paulus et al. reported that 41% of American early
seropositive RA patients had positive ANA results
and higher disease activity.
15 Also, Masi et al.
stated that an ANA positive group demonstrated
a higher degree of bony erosion, which resulted
in poor prognosis of RA.
10 In another report, RF
as well as ANA occurred more frequently in
nodular RA, with serious progress of extraarti-
cular symptoms and radiologic changes.
16 There
was also a report indicating that the level of
immunoglobulin was elevated in serum and syno-
vial fluid to a greater degree in seropositive
patients.
17 These results and ours suggest that
more autoimmune and inflammatory responses
are present in seropositive RA patients.
Regarding RA treatment according to RF pres-
ence, Papadopoulos et al. reported a high fre-
quency of hydroxychloroquine, D-penicillamine,
and methotrexate in seropositive patients.
9 In a
prospective study for an average of 6.2 years,
Mottonen et al. reported that RA patients used 3.3
DMARDs on average.
18 However, as far as we
know, there has been no study made on the fre-
quency of DMARD combination therapy accord-
ing to RF status. Though each DMARD did not
show any difference in usage frequency accordingYoo-Seob Shin, et al.
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to RF status, the frequency of DMARD combina-
tion therapy, especially triple combination thera-
py, was significantly higher in the seropositive
group. From this fact, we infer that the sero-
positive group might need more DMARDs to
control the more severe joint inflammation.
By clinical characteristics and laboratory find-
ings, we verified that more autoimmune and in-
flammatory responses were present in the sero-
positive group. The high frequency of DMARD
combination therapy in treatment, and still higher
inflammatory markers at the last follow-up in the
seropositive group, revealed that seropositive
patients need more DMARD than seronegative
patients, but not enough to control joint inflam-
mation. More aggressive treatment is needed to
control disease activity in seropositive RA
patients.
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